Aclaris Therapeutics
ACRS
136 hedge funds and large institutions have $409M invested in Aclaris Therapeutics in 2026 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 41 increasing their positions, 40 reducing their positions, and 16 closing their positions.
126% more call options, than puts
Call options by funds: $2.57M | Put options by funds: $1.14M
106% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 16
62% more capital invested
Capital invested by funds: $252M → $409M (+$157M)
13.27% more ownership
Funds ownership: 77.29% → 90.56% (+13%)
11% more funds holding
Funds holding: 122 → 136 (+14)
3% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 40
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
Top Sellers
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$7.5M |
| 2 |
D.E. Shaw & Co
New York
|
-$4.03M |
| 3 |
Morgan Stanley
New York
|
-$2.26M |
| 4 |
Renaissance Technologies
New York
|
-$2.1M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.97M |
ACRS Hedge Fund Activity: Q1 2026 in Review
136 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q1 2026, worth a combined $409M — up 62% from $252M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new ACRS positions and 16 closed out — a net gain of 17 holders — while 41 added to existing stakes and 40 trimmed.
The largest buyer was Deep Track Capital, opening a new position worth an estimated $31.5M. The largest seller was Vivo Capital, cutting an estimated $7.5M.
- 136 institutional investors held Aclaris Therapeutics (ACRS) as of Q1 2026, up from 122 in Q4 2025.
- Funds reported $409M of Aclaris Therapeutics stock for Q1 2026, up 62% quarter-over-quarter.
- 33 funds opened new Aclaris Therapeutics positions in Q1 2026 and 16 closed out, a net change of +17 holders.
- The largest Aclaris Therapeutics buyer in Q1 2026 was Deep Track Capital, an estimated $31.5M added.
- The largest Aclaris Therapeutics seller in Q1 2026 was Vivo Capital, an estimated $7.5M sold.
Based on aggregated 13F filings for Q1 2026.